<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607851</url>
  </required_header>
  <id_info>
    <org_study_id>0620181410</org_study_id>
    <nct_id>NCT03607851</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rapid Titration Protocols of Lacosamide</brief_title>
  <official_title>Efficacy and Safety of Rapid Titration Protocols of Lacosamide: An Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three different dose titration schedules are tested to find a way to reduce the titration
      period of lacosamide
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators intend to find a way to reduce the titration period of lacosamide. Dosage
      of lacosamide is increased from 100-200 mg/d to 400 mg/d by three different titration
      schedule. Safety of lacosamide administration is primary endpoint. 50% responder rate
      (seizure reduction) and blood level of lacosamide are investigated for secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2018</start_date>
  <completion_date type="Actual">June 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>6 (rapid titration group) or 8 weeks (conventional titration group)</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of seizure frequency</measure>
    <time_frame>Baseline, 6 weeks (rapid titration group) or 8 weeks (conventional titration group)</time_frame>
    <description>50% responder rate (percentage of patients achieving a 50% or greater reduction in seizure frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lacosamide drug level in the blood</measure>
    <time_frame>2 weeks (rapid titration group) or 4 weeks (conventional titration group)</time_frame>
    <description>lacosamide drug level 1 week after the day of the daily dose of lacosamide reaches 400 mg/day</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>Conventional titration group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid titration group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rapid titration group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide - conventional titration</intervention_name>
    <description>Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID</description>
    <arm_group_label>Conventional titration group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide - rapid titration 1</intervention_name>
    <description>Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week</description>
    <arm_group_label>Rapid titration group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide - rapid titration 2</intervention_name>
    <description>Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID</description>
    <arm_group_label>Rapid titration group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 18-85 years old

          -  Patients diagnosed with focal epilepsy

          -  Patients subjected to the addition of lacosamide to treat focal onset seizures
             according to physician's judgement

          -  Subjects provided informed consent

        Exclusion Criteria:

          -  Subjects who changed other antiepileptic drugs at the beginning of lacosamide
             treatment

          -  Subjects with unstable physical, mental or other disease condition that can impede
             with accurate evaluation or treatment

          -  Subjects with terminal illness or general medical condition that can impede with the
             participation of the clinical trial

          -  Subjects who do not agree with prior consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Doty P, Hebert D, Mathy FX, Byrnes W, Zackheim J, Simontacchi K. Development of lacosamide for the treatment of partial-onset seizures. Ann N Y Acad Sci. 2013 Jul;1291:56-68. doi: 10.1111/nyas.12213. Review.</citation>
    <PMID>23859801</PMID>
  </reference>
  <reference>
    <citation>Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007 Jul;48(7):1308-17.</citation>
    <PMID>17635557</PMID>
  </reference>
  <reference>
    <citation>Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, Sullivan T; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia. 2009 Mar;50(3):443-53. doi: 10.1111/j.1528-1167.2008.01951.x. Epub 2009 Jan 17.</citation>
    <PMID>19183227</PMID>
  </reference>
  <reference>
    <citation>Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, Doty P; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010 Jun;51(6):958-67. doi: 10.1111/j.1528-1167.2009.02496.x. Epub 2010 Jan 27.</citation>
    <PMID>20132285</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Sang Kun Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

